Clinical Trials

Reasons to partner with us

UT Health Physicians have over 100 specialties and subspecialties with 1.6 million patient visits per year at 16 clinics.
The Mays Cancer Center is home to the world-renowned Institute for Drug Development (IDD) where many of the most commonly used FDA-approved anticancer drugs were developed. At any given time, the IDD is testing as many as 60 new drugs and drug combinations and has over 180 clinical trials open for patient enrollment.
UT Dentistry offers 9 specialty clinics staffed by more than 100 faculty experts.
For over a decade, the Association for the Accreditation of Human Research Protection Programs (AAHRPP) has recognized the ethical and effcient operations of our clinical research program.
As a Clinical and Translational Science Award (CTSA) hub, we emphasize the importance of accelerating the research process to translate scientific discovery and offer a master IRB reliance agreement through a SMART IRB platform expediting the regulatory approval process for multisite studies.
San Antonio is the largest minority-majority city in the United States and is home to 7 military installations comprising a large active-duty and retired military population with unique needs.
Through multi-modal strategies, we aim to bring more awareness to our communities about their role in clinical trials.

Learn more about our research enterprise

Contact us

Clinical Trials Office (CTO)
Jason Bates, MBA
210-450-8532
vprcto@uthscsa.edu

Mays Cancer Center Clinical Trials Office
Cindy McKeown, RN, BSN, MPA
210-450-1286
ctofinance@uthscsa

$7,777,671

industry clinical trial revenue in 2019
Over 170

actively recruiting cancer trials
20

institutes and centers with diverse research specialities

Innovation Highlight

Mays Cancer Center

Mays Cancer Center, home to UT Health San Antonio MD Anderson, is the only center in the world conducting a rare Dual Phase 1/2 clinical trial for recurrent glioblastoma to determine the maximum tolerated dose, safety, and efficacy of rhenium nanoliposomes.

Advancing Commercialization

Non-Invasive Screening for Endometriosis

Did you know that every year 170,000 women are diagnosed with endometriosis via laprascopic surgery? Did you also know there is currently no way to diagnose endometriosis non-invasively? This invention aims change that by providing a way to diagnose endometriosis using a non-invasive screen.

Robert J. Chilton, D.O., associate professor of medicine and director of the Cardiac Catheterization Laboratory at the Audie L.

“UT Health San Antonio cardiologists have led pinnacle studies that changed the standard of care for patients. Findings from the multi-site study, COURAGE, remain the gold standard treatment used for patients, worldwide. Our team is proud to lead trials at the South Texas Veteran’s Audie Murphy Hospital, a proven national leader in patient recruitment and retention.”
Robert J. Chilton, D.O., associate professor of medicine and director of the Cardiac Catheterization Laboratory at the Audie L. Murphy Memorial Veterans' Hospital

Spotlight

Breakthrough Drug for T2 Diabetes for People under 18

The Ellipse study enrolled 134 children with Type 2 diabetes in a multi-site study with results showing breakthrough drug liraglutide in combination with metformin demonstrating a robust treatment effect. Read about how UT Health San Antonio was the optimal study site for enrolling diverse populations.
PopUp Star

Through an industry sponsored clinical trials competition called PopUp Star, we developed a grassroots team called YOUniteResearch to raise awareness about the importance of volunteering for clinical research in our communities.
New Drug Approved for Treating Rare Blood Cancer

Dr. Ruben Mesa was part of the international research team that led the development and approval of fedratinib, becoming the 2nd drug that can be used to treat myelofibrosis, after huge success in Phase 3 trial, JAKARTA.